Administrative Core

本申请旨在为阐明SLAMF受体在急性髓细胞白血病发病机制中的作用提供支持。 系统性红斑狼疮(SLE)的最终目标是开发基于SLAMF的治疗策略 这一点也适用于SLE患者。因为我们对系统性红斑狼疮细胞的研究结果 患者和我们在转基因小鼠身上的令人兴奋的发现，这些小鼠会产生与狼疮相关的自身免疫， 我们现在已经有了系统来剖析细胞相互作用机制和由 SLAMF受体参与自身抗原耐受性的控制和人类的发病 SLE。 这些见解和工具是项目项目应用程序的基础，该项目名为：SLAM家庭 三个相互关联的项目和两个支持核心的“受体控制的系统性红斑狼疮路径”。 P#1 Slamf3、Slamf5和Slamf6受体诱导的小鼠狼疮通路。 人和小鼠SLAMF4？SLAMF2受体/配体相互作用的P#2功能分析 和人类系统性红斑狼疮。 人类SLAMF受体在SLE免疫细胞中的P#3功能PL： 核心基因老鼠的核心。 核心B管理核心。 在本管理核心中，我们特别建议： SA#1.通过以下方式在项目的三个项目中促进研究人员之间的科学互动 频繁的会议；特别是通过简化从小鼠实验到翻译的过渡 使用SLE患者的材料进行研究。 SA#2.促进试剂、技术信息和患者材料的交流。 SA#3.促进计划成员之间的管理交互。

This application seeks support for elucidating the role of the SLAMF receptors in the pathogenesis of Systemic Lupus Erythematosus (SLE) with the ultimate goal to develop SLAMF-based therapeutic strategies that can be applied to SLE patients. Because of the outcomes of our studies with cells derived from SLE patients and our exciting findings with genetically altered mice, which develop lupus-related autoimmunity, we now have the systems in place to dissect how cell interaction mechanisms and signaling initiated by the SLAMF receptors contribute to the control of tolerance to autoantigens and to the pathogenesis of human SLE. These insights and tools are the basis for a Program Project application entitled: "SLAM FAMILY RECEPTOR CONTROLLED PATHWAYS TO SLE" for three interlinked projects and two supporting Cores. P#1 The Slamf3, Slamf5 and Slamf6 receptor-induced pathways to murine lupus. P#2 Functional analyses of human and mouse SLAMF4«SLAMF2 receptor / ligand interactions in murine and human SLE. P#3 Function of human SLAMF receptors in SLE immune cells. PL: Core A Genetic Mouse Core. Core B Administrative Core. In this Administrative Core we specifically propose to: SA#1. Nurture scientific interactions between the investigators in the three projects in the program through frequent meetings; particularly by streamlining the transition from mouse experiments to Translational Research with materials from SLE patients. SA#2. Facilitate the exchange of reagents, technical information and patient materials. SA#3. Facilitate administrative interactions between the members of the program.